Table 1 Distribution of INH-resistant MTB isolates among demographic and clinical characteristics between 2005 and 2015 in this study
Characteristics | Â | No. (%) of isolates | P value | OR 95% CI | ||
|---|---|---|---|---|---|---|
2005 (n = 273) | 2015 (n = 269) | |||||
INH-R (n = 82) | INH-S | INH-R | INH-S | |||
(n = 191) | (n = 105) | (n = 164) | ||||
Sex | ||||||
 Men | 45(54.9) | 123(64.4) | 69(65.7) | 103(62.8) | 0.01 | 1.83 (1.16–2.89) |
 Women | 37(45.1) | 68(35.6) | 36(34.3) | 61(37.2) | 0.78 | 1.08 (0.61–1.93) |
Age group (years) | ||||||
 <25 | 9(11.0) | 22(11.5) | 9(8.6) | 19(11.6) | 0.80 | 1.16(0.38–3.51) |
 25–44 | 34(41.5) | 72(37.7) | 42(40.0) | 54(32.9) | 0.09 | 1.65(0.93–2.92) |
 45–64 | 28(34.1) | 64(33.5) | 39(37.1) | 59(36.0) | 0.18 | 1.51 (0.83–2.76) |
 >64 | 11(13.4) | 33(17.3) | 15(14.3) | 32(19.5) | 0.47 | 1.41(0.56–3.52) |
Treatment History | ||||||
 New case | 38(46.3) | 131(68.6) | 63(60.0) | 126(76.8) | 0.02 | 1.72(1.08–2.76) |
 Re-treated | 44(53.7) | 60(31.4) | 42(40.0) | 38(23.2) | 0.17 | 1.51(0.84–2.71) |